MabThera/Rituxan

Imbruvica and Gazyvo approved in first non-chemo CLL use

The approval is also good news for Roche and its drug Gazyvo (obinutuzumab) which the company is trying to prove as superior next-generation version of MabThera/Rituxan (rituximab) which is

CHMP backs Sanofi’s all-oral sleeping sickness drug

remission with minimal residual disease greater than or equal to 0.1%, and also backed Roche’s MabThera (rituximab) for adults with severe, active granulomatosis with polyangiitis and microscopic polyangiitis in

Roche and AbbVie prepare to move Venclexta into first-line CLL

Gazyva is a follow-up to Roche’s big-selling Rituxan/MabThera (rituximab) anti-CD20 drug – a mainstay of CLL therapy given alongside chemotherapy – and was approved alongside chlorambucil for ... Venclexta is a key growth product for both companies

Roche’s new flu pill Xofluza approved in US

Roche is in need of a new set of innovative products, as its older generation of blockbusters, Avastin, Herceptin and MabThera/Rituxan come under competition from biosimilars.

Celgene to launch five new products through to 2020

Also on the agenda is a closer look at the AUGMENT trial of Revlimid with Roche’s Rituxan (rituximab) in relapsed/refractory indolent lymphoma.

[ Previous 5 results ] 2 3 4 5 6 7 8 9 10 11 [ Next 5 results ]